Results 231 to 240 of about 3,942,953 (265)
Pan-cancer analysis identifies JMJD6 as an oncogene and prognostic biomarker. [PDF]
Liu L, Li T, He J, Liu G.
europepmc +1 more source
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami +7 more
wiley +1 more source
C17orf75 (Njmu-R1) promotes hepatocellular carcinoma progression: a pan-cancer analysis and experimental validation. [PDF]
Liang H +6 more
europepmc +1 more source
Lactate‐driven endometrial cancer relapse is mediated by enzymatic protein modification. Elevated lactate levels activate AARS1, which catalyzes K280 lactylation of IGF2BP3, therefore stabilizing HMGA2 mRNA and promoting tumor stemness and recurrence.
Peng Jiang +11 more
wiley +1 more source
Pan-Cancer Quantification of Driver Alteration Transmission Across Molecular Layers Reveals Limited Propagation to Protein Abundance. [PDF]
Nakano H.
europepmc +1 more source
PTBP1‐mediated alternative splicing drives a pathogenic switch to the DNAJB6b isoform in everolimus‐resistant clear cell renal cell carcinoma. This splicing event programs a positive feedback loop including EIF4B/PKIB/AKT/mTOR, promoting aggressive therapy resistance.
Xiu‐wu Pan +18 more
wiley +1 more source
Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8<sup>+</sup> T cell immunotherapy responses. [PDF]
Li L +24 more
europepmc +1 more source
<i>CDKN2AIPNL</i>: a potential pan-cancer biomarker. [PDF]
Yuan Y +6 more
europepmc +1 more source
ICIsAtlas reveals a suppressive NK cell niche in pan-cancer immunotherapy profiles. [PDF]
Xie Y +16 more
europepmc +1 more source
Pan-cancer investigation identifies ARL4A as a prospective therapeutic indicator for thyroid cancer. [PDF]
Men Y +14 more
europepmc +1 more source

